COURAGE Trial: Bad News Again for Stents at ACC, Or Is It?

01 Apr 2007

For the second year in a row, results from a clinical trial announced at the annual American College of Cardiology (ACC) conference appeared to be bad news for coronary stents. The outcomes from the COURAGE trial, announced at this year's ACC meeting in New Orleans at the end of March, found that angioplasty with stenting did not reduce the risk of major adverse cardiovascular events when added to optimal medical therapy.

For the second year in a row, results from a clinical trial announced at the annual American College of Cardiology (ACC) conference appeared to be bad news for coronary stents. The outcomes from the COURAGE trial, announced at this year’s ACC meeting in New Orleans at the end of March, found that angioplasty with stenting did not reduce the risk of major adverse cardiovascular events (MACE) when added to optimal medical therapy (OMT, which includes both pharmacological therapy and lifestyle changes) as an initial strategy for treating patients with stable coronary artery disease.

The COURAGE (Clinical Outcomes Utilizing Percutaneous Coronary Revascularization and Aggressive Guideline-Driven Drug Evaluation) study results capped off a year in...

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

15 Jul 2025

• By Ashley Yeo

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

14 Jul 2025

• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

10 Jul 2025

• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

08 Jul 2025

• By David Wild

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.